Tibsovo Alternatives Compared
| Tibsovo (ivosidenib) | Durvalumab | Ziihera (zanidatamab) |
|
|---|
| Tibsovo (ivosidenib) | Durvalumab | Ziihera (zanidatamab) |
|
|||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
Prescription only
Prescribed for Biliary Tract Tumor, Acute Myeloid Leukemia, Myelodysplastic Syndrome. Tibsovo may also be used for purposes not listed in this medication guide. |
Prescription only
Prescribed for Non Small Cell Lung Cancer, Small Cell Lung Cancer, Biliary Tract Tumor, Bladder Cancer, Hepatocellular Carcinoma, Endometrial Cancer. Durvalumab may also be used for purposes not... View more |
Prescription only
Prescribed for Biliary Tract Tumor. Ziihera may also be used for purposes not listed in this medication guide. |
Related suggestions Biliary Tract Tumor
|
|||||||||||||||
| More about Tibsovo (ivosidenib) | More about Durvalumab | More about Ziihera (zanidatamab) | ||||||||||||||||
| Ratings & Reviews | ||||||||||||||||||
|
Be the first to share your experience with this drug. |
Durvalumab has an average rating of 7.5 out of 10 from a total of 8 ratings on Drugs.com. 63% of reviewers reported a positive effect, while 0% reported a negative effect. |
Be the first to share your experience with this drug. |
||||||||||||||||
| Side Effects Experienced by Users Side effects are reported in Drugs.com user reviews and not clinically verified. | ||||||||||||||||||
|
View all Tibsovo side effects |
View all Durvalumab side effects |
View all Ziihera side effects |
||||||||||||||||
| Drug Class | ||||||||||||||||||
| Generic Availability | ||||||||||||||||||
|
N/A |
N/A |
|||||||||||||||||
| Pricing and Coupons * Prices are without insurance | ||||||||||||||||||
View all Tibsovo prices |
We could not find an exact match for this medicine. Try searching the Price Guide directly. |
View all Ziihera prices |
||||||||||||||||
| Dosage Forms | ||||||||||||||||||
|
N/A |
|
||||||||||||||||
| Brand Names | ||||||||||||||||||
|
N/A |
Imfinzi |
N/A |
||||||||||||||||
| Half Life Drug half-life is the time required for plasma concentration to reduce to half its original value. | ||||||||||||||||||
|
129 hours |
408 hours |
504 hours |
||||||||||||||||
| CSA Schedule 1 View glossary of CSA terms | ||||||||||||||||||
|
Not a controlled drug
Is not subject to the Controlled Substances Act. |
Not a controlled drug
Is not subject to the Controlled Substances Act. |
Not a controlled drug
Is not subject to the Controlled Substances Act. |
||||||||||||||||
| Pregnancy Category | ||||||||||||||||||
|
Summary unavailable. See the full pregnancy warnings document. |
Summary unavailable. See the full pregnancy warnings document. |
Summary unavailable. See the full pregnancy warnings document. |
||||||||||||||||
| Drug Interactions | ||||||||||||||||||
|
A total of 583 drugs are known to interact with Tibsovo:
|
A total of 630 drugs are known to interact with Durvalumab:
|
A total of 96 drugs are known to interact with Ziihera:
|
||||||||||||||||
| Alcohol/Food/Lifestyle Interactions | ||||||||||||||||||
|
No known alcohol/food interactions. This does not necessarily mean no interactions exist. Always consult your healthcare provider. |
No known alcohol/food interactions. This does not necessarily mean no interactions exist. Always consult your healthcare provider. |
||||||||||||||||
| Disease Interactions | ||||||||||||||||||
| First Approval Date | ||||||||||||||||||
|
July 20, 2018 |
May 01, 2017 |
November 20, 2024 |
||||||||||||||||
| WADA Class View classifications | ||||||||||||||||||
|
N/A |
N/A |
N/A |
||||||||||||||||
| More Information | ||||||||||||||||||
| Patient Resources | ||||||||||||||||||
| Professional Resources | ||||||||||||||||||
| Related Treatment Guide | ||||||||||||||||||
1 The Controlled Substances Act (CSA) schedule information displayed applies to substances regulated under federal law. There may be variations in CSA schedules between individual states.
See also:
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.